RxDoctor Payments Data

Carla Rosario-Illanas, MD

Interventional Cardiology · Carolina, PRNPI 1710374806

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $8,752 of the $13,407 with a category attached, or 65.3%. Boston Scientific accounts for 70.3% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2023 at $9,800 and has fallen 89.2% since, to $1,063 in 2025.

$13,407in general payments, 2019–2025

Across 133 payments — averaging $100.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$9K
  • Medtronic$900
  • Boehringer Ingelheim$573
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$549
  • PBG Puerto Rico LLC$428
  • E.r. Squibb & Sons, L.L.C.$319
  • plus $1K from 13 others

What the payments were for

  • Travel & lodging$8,75265%
  • Food & beverage$4,63635%
  • Education$200%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,407 in reported general payments places this provider in the 55th percentile of 39 interventional cardiology providers in Puerto Rico.

See all interventional cardiology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$21,800
Medicare patients
74
Services billed
282

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban170$115,280
JardianceEmpagliflozin148$106,550
XareltoRivaroxaban61$45,434
FarxigaDapagliflozin Propanediol17$14,401
EntrestoSacubitril/Valsartan19$13,001
BrilintaTicagrelor21$12,401
Atorvastatin Calcium798$7,624
Metoprolol Succinate591$7,151
Repatha SureclickEvolocumab11$6,315
Irbesartan264$6,259
Rosuvastatin Calcium575$5,729
Candesartan Cilexetil69$5,008
Losartan Potassium531$4,758
Ranolazine ErRanolazine30$3,268
Ezetimibe229$3,234

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$20$115,280170 claims
Boehringer IngelheimJardiance$573$106,550148 claims
Johnson & JohnsonXarelto$99$45,43461 claims
AstraZenecaFarxiga, Brilinta$239$26,80238 claims
NovartisEntresto$45$13,00119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 39 interventional cardiology providers in Puerto Rico.

Other interventional cardiology in Carolina

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →